Category:

Hiring Hits 7-Month Low as Fed Eyes Soft Landing

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Job openings and hiring rates declined in June, pointing to a cooling labor market.
– Slower labor momentum may support interest rate cuts, benefiting small-cap stocks.
– Wage and recruitment pressure may ease for lean growth-stage companies.

U.S. job openings and hiring took a step back in June, signaling a potential shift in the labor market that middle-market investors should watch closely — not fear. According to the Bureau of Labor Statistics, job openings slid to 7.44 million, while hiring dipped to 5.2 million, the lowest level seen since November 2024.

While the headlines suggest cooling momentum, the broader story may hold more nuanced opportunities, especially for investors focused on small and micro-cap companies. A slower labor market, in combination with steady inflation data, could strengthen the case for the Federal Reserve to hold — or even cut — interest rates in the coming months. That shift would support capital access and investor appetite for growth-stage businesses that have been squeezed by tight monetary policy.

Though hiring dipped, layoffs remain notably low, and the quits rate — a proxy for worker confidence — held steady at 2%. Economists are describing this as a market in “stasis,” but for long-term investors, the pause could be a prelude to renewed acceleration.

For small-cap companies, especially those in labor-sensitive sectors like retail, logistics, and light manufacturing, a cooling hiring pace may relieve wage pressure and improve margins. It also puts less strain on recruitment, potentially helping leaner firms maintain productivity without costly hiring sprees.

Meanwhile, private sector ADP data revealed a loss of 33,000 jobs in June — the first negative reading since March 2023 — and consumer confidence continues to weaken. Yet, this cooling sentiment could signal that wage inflation, a concern for the Fed, is abating. Should that trend continue, it strengthens the case for interest rate cuts by year-end — a move that historically benefits risk assets and small-cap equities more than their large-cap peers.

This week’s data will culminate in Friday’s July jobs report, which economists expect to show 101,000 jobs added and a rise in unemployment to 4.2%. If confirmed, it could validate investor bets on a looser monetary stance and provide a tailwind for undervalued companies that have struggled under high-rate conditions.

For middle-market investors, this is a moment to dig deeper into companies with strong fundamentals but weakened valuations. Lower rates could reignite M&A activity and growth funding in the lower end of the public markets. And while the broader labor market narrative may appear sluggish, it’s precisely this cooling that could set the stage for a more accommodative environment in the quarters ahead.

Release – Perfect Corp. Reports Unaudited Financial Results for the Three Months and the Six Months Ended June 30, 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PERF

July 29, 2025

    NEW YORK–(BUSINESS WIRE)– Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty and fashion industries, today announced its unaudited financial results for the three months ended June 30, 2025 and the six months ended June 30, 2025. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty and fashion industries, today announced its unaudited financial results for the three months ended June 30, 2025 and the six months ended June 30, 2025.

    Financial Results for the Three Months Ended June 30, 2025

    Revenue

    Total revenue was $16.3 million for the three months ended June 30, 2025, compared to $13.9 million in the same period of 2024, an increase of 17.6%. The increase was primarily due to strong growth momentum in the revenue of mobile app and web services subscriptions.

    • AI- and AR- cloud solutions and subscription revenue was $14.9 million for the three months ended June 30, 2025, compared to $12.9 million in the same period of 2024, an increase of 15.6%. The increase was driven by the continued revenue growth of YouCam mobile app and web services subscriptions, the growing popularity among consumers of Generative AI technologies and AI editing features for photos and videos, and the stable demand for the Company’s online virtual product try-on solutions from brand customers.
    • Licensing revenue was $0.9 million for the three months ended June 30, 2025, compared to $0.7 million in the same period of 2024, an increase of 36.5%.

    Gross Profit

    Gross profit was $12.3 million for the three months ended June 30, 2025, compared with $11.0 million in the same period of 2024, an increase of 11.6%. Gross margin was 75.3% for the three months ended June 30, 2025, slightly down from 79.3% in the same period of 2024. The decrease in gross margin was primarily due to the increase in third-party payment processing fees paid to digital distribution partners, such as Google and Apple, driven by the steady growth in our YouCam mobile app subscription revenue. In addition, the increases in AI server computing cost, resulting from the growing demand for premium features powered by generative AI services, also contributed to the decrease in gross margin

    Total Operating Expenses

    Total operating expenses were $13.8 million for the three months ended June 30, 2025, compared with $12.4 million in the same period of 2024, an increase of 10.8%. The increase was primarily due to increases in research and development and sales and marketing expenses, which were partially offset by a decrease in general and administrative expenses in the second quarter of 2025.

    • Sales and marketing expenses were $7.8 million for the three months ended June 30, 2025, compared to $7.0 million during the same period of 2024, an increase of 11.3%. This increase was primarily due to an increase in marketing events and advertising expenses related to our mobile apps and web services subscription.
    • Research and development expenses were $4.0 million for the three months ended June 30, 2025, compared to $3.0 million during the same period of 2024, an increase of 35.5%. The increase was caused by two main factors: (i) the foreign exchange impact caused by the depreciation of the U.S. dollar against New Taiwan dollar elevated personnel costs for our Taiwan-based development team, and (ii) the increase in research and development headcount and related compensation expenses following the acquisition of Wannaby Inc. (“Wannaby”).
    • General and administrative expenses were $2.0 million for the three months ended June 30, 2025, compared to $2.4 million during the same period of 2024, a decrease of 18.0%. The decrease was primarily due to reduced corporate insurance premium and external professional service fees.

    Net Income

    Net income was $0.2 million for the three months ended June 30, 2025, compared to $0.8 million during the same period of 2024, a decrease of 72.9%. The decrease in net income was primarily due to (i) higher third-party payment processing fees, (ii) higher Taiwan personnel costs due to foreign exchange impact by a weaker U.S. dollar, (iii) increases in operating expenses after the acquisition of Wannaby, and (iv) lowered interest income due to decreases in interest rates on the Company’s cash reserve.

    Adjusted Net Income (Non-IFRS)1

    Adjusted net income was $0.4 million for the three months ended June 30, 2025, compared to $1.3 million in the same period of 2024, a decrease of 68.3%.

    Operating Cash Flow

    Operating cash flow was $3.7 million in the three months ended June 30, 2025, compared to $2.0 million in the same period of 2024, an increase of 83.4%.

    Financial Results for the Six Months Ended June 30, 2025

    Revenue

    Total revenue was $32.4 million for the six months ended June 30, 2025, compared to $28.2 million in the same period of 2024, an increase of 14.8%.

    • AI- and AR- cloud solutions and subscription revenue was $29.0 million for the six months ended June 30, 2025, compared to $25.3 million in the same period of 2024, an increase of 14.5%. The increase was driven by the continued revenue growth of YouCam mobile app and web services subscriptions.
    • Licensing revenue was $2.6 million for the six months ended June 30, 2025, compared to $2.3 million in the same period of 2024, an increase of 12.1%.

    Gross Profit

    Gross profit was $24.8 million for the six months ended June 30, 2025, compared with $22.2 million in the same period of 2024, an increase of 11.5%. Gross margin was 76.6% for the six months ended June 30, 2025, slightly down from 78.8% in the same period of 2024.

    Total Operating Expenses

    Total operating expenses were $26.4 million for the six months ended June 30, 2025, compared with $24.8 million in the same period of 2024, an increase of 6.4%. The increase was primarily due to increases in research and development and sales and marketing expenses, which were partially offset by a decrease in general and administrative expenses during the period.

    • Sales and marketing expenses were $15.2 million for the six months ended June 30, 2025, compared to $14.2 million during the same period of 2024, an increase of 7.0%.
    • Research and development expenses were $7.6 million for the six months ended June 30, 2025, compared to $6.0 million during the same period of 2024, an increase of 26.4%.
    • General and administrative expenses were $3.7 million for the six months ended June 30, 2025, compared to $4.6 million during the same period of 2024, a decrease of 19.7%.

    Net Income

    Net income was $2.5 million for the six months ended June 30, 2025, compared to $1.4 million during the same period of 2024, an increase of 79.3%.

    Adjusted Net Income (Non-IFRS)1

    Adjusted net income was $2.4 million for the six months ended June 30, 2025, compared to $2.8 million in the same period of 2024, a decrease of 12.9%.

    Operating Cash Flow

    Operating cash flow was $8.0 million in the six months ended June 30, 2025, compared to $5.5 million in the same period of 2024, an increase of 44.7%. The Company continues to invest in growth while maintaining a healthy cash flow to support business operations underscoring the Company’s operational health and sustainability.

    Capital Resource

    As of June 30, 2025, the Company’s cash and cash equivalents remained stable at $125.3 million (or $167.8 million when including 6-month time deposits of $36.3 million and money market funds of $6.2 million, which are classified as current financial assets at amortized cost and current financial assets at fair value through profit or loss under IFRS, respectively), compared to $127.1 million (or $165.9 million when including time deposits and money market funds) as of December 31, 2024.

    Key Business Metrics

    • The number of active subscriber for the Company’s YouCam mobile beauty app and web services was 960,000 as of June 30, 2025, compared to over 919,000 as of June 30, 2024, an increase of 4.4%.
    • As of June 30, 2025, the Company’s cumulative customer base included 818 brand clients, with over 914,000 digital stock keeping units (“SKUs”) for makeup, haircare, skincare, shoes, bags, eyewear, watches and jewelry products, compared to 686 brand clients and over 774,000 digital SKUs as of June 30, 2024. The number of Key Customers 2 of the Company as of June 30, 2025 was 139 compared to 151 as of June 30, 2024. Half of the net decrease in Key Customer count was due to customers being downgraded as a result of lower spending during the period, while the other half was driven by customer churn amid ongoing macroeconomic challenges in the beauty and luxury sectors.

    CEO Remarks and Business Outlook for 2025

    Ms. Alice H. Chang, the Founder, Chairwoman, and Chief Executive Officer of Perfect commented, “Our mobile app and web subscription business continues to demonstrate strong momentum, now growing significantly faster than our enterprise segment. B2C subscriptions have become the primary driver of our overall revenue growth, fueled by sustained demand for our photo- and video-based generative AI features. While the enterprise business remains strategic, many clients are approaching new AI initiatives with caution amid broader macroeconomic uncertainty. As such, we maintain a prudent near-term outlook for B2B.

    2025 is shaping up to be a transformative year for Perfect Corp. Artificial intelligence is no longer a supporting capability. It is the foundation of both our product roadmap and operational strategy. Our expanded investment in generative AI is delivering tangible results. The YouCam product family now integrates cutting-edge features such as text-to-video, photo-to-video, and AI-powered image and video enhancements, making it an essential tool for mobile-first creators. These innovations are enabling users to produce high-quality content in minutes, accelerating engagement across our platforms.

    Internally, AI is driving operational excellence. From workflow automation and advanced analytics to virtual assistants and enhanced forecasting, AI is helping us scale more efficiently and deliver greater value. These gains benefit both our global subscriber base and the 800+ beauty and fashion brands that rely on Perfect Corp. to power their digital experiences.

    Looking ahead, we remain fully committed to advancing our generative AI capabilities. We are expanding our R&D pipeline and scaling our infrastructure to anticipate and meet evolving user demands. Our strategic focus is clear: deliver breakthrough user experiences that are faster, more personalized, and more engaging.

    For the second half of 2025, we see three key growth catalysts:

    1. Continued momentum in our GenAI-powered B2C apps and web subscriptions
    2. A stable and resilient enterprise pipeline
    3. Operational efficiency driven by AI-enabled processes

    With innovation, accessibility, and execution at the core of our strategy, we are confident in our ability to create sustained value for users, brand partners, employees, and shareholders.

    Based on the revenue growth momentum in both YouCam mobile apps and web service subscriptions and the sustained demand for enterprise SaaS solution, the Company reiterates its full year 2025 revenue guidance of 13.0% to 14.5% year-over-year, compared to 2024. This outlook reflects our latest view of market dynamics and internal performance, and is subject to adjustment should conditions change.”

    About Perfect Corp.

    Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR- powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect’s direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.

    Forward-Looking Statements

    This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.

    Use of Non-IFRS Financial Measures

    This press release and accompanying tables contain certain non-IFRS financial measures, including adjusted net income, as supplemental metrics in reviewing and assessing Perfect’s operating performance and formulating its business plan. Perfect defined these non-IFRS financial measures as follows:

    Adjusted net income (loss) is defined as net income (loss) excluding one-off transaction costs3, non-cash equity-based compensation, and non-cash valuation (gain)/loss of financial liabilities. For a reconciliation of adjusted net income (loss) to net income (loss), see the reconciliation table included elsewhere in this press release.

    Non-IFRS financial measures are not defined under IFRS and are not presented in accordance with IFRS. Non-IFRS financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-IFRS financial measures. In addition, the non-IFRS financial measures Perfect uses may differ from the non-IFRS measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-IFRS financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with IFRS. The items excluded from our adjusted net income are not driven by core results of operations and render comparison of IFRS financial measures with prior periods less meaningful. We believe adjusted net income provides useful information to investors and others in understanding and evaluating our results of operations, as well as providing a useful measure for period-to-period comparisons of our business performance. Moreover, such non-IFRS measures are used by our management internally to make operating decisions, including those related to operating expenses, evaluate performance, and perform strategic planning and annual budgeting.

    View full release here.

    Investor Relations Contact
    Investor Relations, Perfect Corp.
    Email: Investor_Relations@PerfectCorp.com

    Release – Graham Corporation Awarded $25.5 Million Follow On Order to Provide Engineered Products for MK48 Mod 7 Heavyweight Torpedo

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on GHM

    July 29, 2025 8:00am EDT Download as PDF

    BATAVIA, N.Y.–(BUSINESS WIRE)– Graham Corporation (NYSE: GHM) (“GHM” or “the Company”), a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space industries, today announced that it has been awarded a follow-on order to produce mission-critical hardware for the MK48 Mod 7 Heavyweight Torpedo program valued at approximately $25.5 million.

    Matthew J. Malone, President and CEO, commented, “This follow-on award underscores our competitive position as a trusted supplier of mission-critical components to the U.S. Navy and allied defense programs. It reflects the strength of our engineering capabilities, highly skilled and engaged workforce, and precision manufacturing expertise. We’ve made targeted investments to improve operational efficiency to fulfill current and future demand, positioning us to drive recurring revenue, expand margins, and deliver long-term value to shareholders.”

    Graham manufactures and tests the alternators and regulators for the MK48 Mod 7 Heavyweight Torpedo through its Barber-Nichols subsidiary in Arvada, CO.

    About Graham Corporation
    Graham is a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy, & Process, and Space industries. Graham Corporation and its family of global brands are built upon world-renowned engineering expertise in vacuum and heat transfer, cryogenic pumps, and turbomachinery technologies, as well as its responsive and flexible service and the unsurpassed quality customers have come to expect from the Company’s products and systems. Graham Corporation routinely posts news and other important information on its website, grahamcorp.com, where additional information on Graham Corporation and its businesses can be found.

    Safe Harbor Regarding Forward Looking Statements
    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

    Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “future,” and other similar words. All statements addressing operating performance, events, or developments that Graham Corporation expects or anticipates will occur in the future, including but not limited to, profitability of future projects and the business, its ability to deliver to plan, its ability to secure future projects and applications, are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Graham Corporation’s most recent Annual Report filed with the Securities and Exchange Commission (the “SEC”), included under the heading entitled “Risk Factors”, and in other reports filed with the SEC.

    Should one or more of these risks or uncertainties materialize or should any of Graham Corporation’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Graham Corporation’s forward-looking statements. Except as required by law, Graham Corporation disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

    For more information, contact:
    Christopher J. Thome
    Vice President – Finance and CFO
    Phone: (585) 343-2216

    Tom Cook
    Investor Relations
    (203) 682-8250
    Tom.Cook@icrinc.com

    Source: Graham Corporation

    Released July 29, 2025

    Release – Conduent Expands Finance and Procurement Capabilities with Fairmarkit’s AI-Powered Technologies including GenAI

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on CNDT

    July 29, 2025

    Finance & Accounting Services Commercial Sector

    The combination of Conduent’s and Fairmarkit’s industry expertise and technology delivers real savings and revolutionizes the sourcing process.

    FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services provider, today announced a strategic collaboration with Fairmarkit, an autonomous AI-powered sourcing platform designed to optimize procurement workflows from RFP to award for all levels of spend. The Fairmarkit sourcing technology will complement Conduent’s FastCap® Finance Analytics, which improves financial performance by identifying cost-saving opportunities within procurement and spend management.

    Fairmarkit Brings World-Class AI Tools to Drive More Powerful Results
    Fairmarkit’s platform utilizes the most impactful AI technologies to enable robust procurement support:

    • Streamline Procurement Processes – Support full range of workflow processes from sourcing strategic suppliers to managing RFP responses and awards to drive greater efficiency and visibility across suppliers.
    • Enhance Sourcing Accuracy – Use AI-driven insights to refine purchasing decisions.
    • Expand Cost-Saving Opportunities – Offer real-time data analytics to optimize spend management.

    The data from FastCap, a finance analytics tool that prevents and recovers payment errors, can identify opportunities to improve tail spend. Combining the capabilities of FastCap and Fairmarkit automates the capture of those tail spend opportunities to accelerate savings.

    By preventing or recovering overpayments, FastCap identified over $800 million of savings and recoveries, representing up to 10% of addressable spend, since 2021. Through spend compliance, automated bidding and enhanced supply options, FastCap and Fairmarkit together could drive 3-6% more in savings for companies.

    “FastCap has resulted in significant savings for clients, while helping to drive contract compliance, risk reduction and financial visibility,” said Mike McDaniel, Group President of Commercial Solutions at Conduent. “We will continue to expand FastCap’s capabilities to solve key client challenges and generate business outcomes. Collaborating with innovative solution partners like Fairmarkit helps our clients further advance their objectives and create stronger financial results.”

    “We’re thrilled to partner with Conduent to bring the power of AI-powered sourcing to a broader range of procurement teams,” said Allison Yount, Vice President of Partnerships and Business Development at Fairmarkit. “Conduent’s deep expertise in procurement transformation, combined with Fairmarkit’s intelligent technology and experience working with the world’s leading procurement teams, creates a compelling solution that empowers organizations to optimize their spend, streamline processes, and unlock new value from their sourcing activities.”

    Conduent’s Finance, Accounting and Procurement Solutions —now enhanced by Fairmarkit’s capabilities—accelerate cost savings while streamlining procurement processes, empowering organizations to make smarter, data-driven decisions.

    About Fairmarkit
    Fairmarkit is the premiere AI-powered autonomous sourcing solution for enterprise procurement, empowering teams to manage all types of spend more efficiently from demand to award. Fairmarkit’s award-winning AI product suite delivers unparalleled efficiency to each step of the procurement cycle, equipping teams to source better, faster and cheaper with greater risk mitigation. Procurement teams from Amazon, BP, Goodyear, Nestle and other global powerhouses are using Fairmarkit to take on more spend under management, enhance compliance, strengthen supplier relationships, and achieve record savings. For more information, visit Fairmarkit.com.

    About Conduent
    Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

    Forward-Looking Statements
    This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “looking to continue,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” “as we progress,” “going to,” “path from here forward,” “think,” “path to deliver,” “from here,” “on track,” “remain” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements, including, but not limited to, statements regarding the planned adoption of technology, including all statements made under the first paragraph under the caption “Future EMV Chip and Mobile Wallet Integration” within this release. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make.

    Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to those factors that are set forth in the “Risk Factors” section, the “Legal Proceedings” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other sections in our 2024 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.

    Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit http://twitter.com/Conduent , http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent .

    Trademarks
    Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

    Media Contacts

    Sean Collins

    Conduent

    Sean.Collins2@conduent.com

    +1-310-497-9205

    David Chen

    Conduent

    ir@conduent.com

    Lane Kearney

    Fairmarkit

    Fairmarkit@corporateink.com

    Release – GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on GOVX

      EMA Scientific Guidance, Global Surge in Clade I Mpox, and Aid Shortfalls Drive Urgent Need for Scalable, Equitable Vaccine Solutions

      Atlanta, GA – July 29, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today announced an expedited development strategy for its GEO-MVA Mpox vaccine candidate, following newly reaffirmed global emergency status by the World Health Organization (WHO), a record-setting surge in Mpox cases across Africa, and recent favorable scientific advice from the European Medicines Agency (EMA) supporting an expedited development path for GEO-MVA.

      These developments reinforce the urgent global need for diversified, scalable vaccine platforms amid critical shortages and growing international spread of more virulent Mpox strains.

      Global Mpox Cases Surge Beyond 2024 Totals; Africa’s Health Systems Overwhelmed

      More than 21,000 confirmed Mpox cases have been reported in 13 African countries so far in 2025 – exceeding the total case count for all of 2024 – with numbers expected to double by year-end. Sierra Leone, Malawi, and the Democratic Republic of the Congo (DRC) are among the most heavily impacted, with healthcare systems under severe strain due to significant U.S. and European aid reductions.

      Only 700,000 Mpox vaccine doses have been administered across 11 countries, and key nations like Sierra Leone are still awaiting most of their requested supply. In the DRC alone, over 60,000 suspected cases and nearly 1,800 deaths have been reported. The crisis is being further complicated by armed conflict, collapsing infrastructure, and the emergence of Clade I and Clade 1a Mpox variants, which exhibit greater severity and transmissibility.

      Global Spillover and WHO Emergency Status Highlight Urgency

      The WHO’s International Health Regulations (IHR) Emergency Committee reconvened on July 5, 2025, and officially reaffirmed Mpox as a Public Health Emergency of International Concern (PHEIC). The WHO’s Situation Report #55, released July 11, underscores the worsening multi-country outbreak and mounting strain on surveillance, laboratory, and response systems.

      International spread is accelerating. Clade I Mpox cases have now been confirmed in China, the United Kingdom, Italy, and the United States. U.S. health officials have identified five travel-related Clade I cases since late 2024, including a confirmed case in Massachusetts in June 2025, while wastewater testing confirms silent community transmission.

      The CDC continues to emphasize surveillance efforts – including wastewater and diagnostic testing – but warns that current tools are insufficient to contain a broader outbreak without expanded vaccine access and supply.

      EMA Guidance Supports Expedited GEO-MVA Pathway

      GeoVax has received favorable scientific advice from the European Medicines Agency (EMA) regarding the development of GEO-MVA. The EMA guidance supports a streamlined regulatory pathway, enabling GeoVax to pursue expedited development and potential conditional approval of GEO-MVA as an additional Mpox vaccine candidate in the EU. This guidance strengthens the GEO-MVA development program’s relevance to global procurement programs, including those of WHO and UNICEF.

      GeoVax Response: Acceleration, Scalability, and Equitable Access

      In light of these developments, GeoVax is implementing a comprehensive, expedited development strategy:

      • Clinical Development Acceleration: Finalizing fill-finish manufacturing and initiating human trials to evaluate safety and immunogenicity against both Clade I and Clade II variants. Regulatory planning includes immuno-bridging studies for global deployment.
      • Advanced MVA Manufacturing Platform: Development is underway for GEO-MVA’s production using a continuous avian cell line system, enabling rapid, large-scale, and cost-effective production – addressing a key shortfall of the incumbent egg-based method.
      • International Collaboration: Engaging health authorities, NGOs, and regional partners across Africa to ensure vaccine readiness and coordinated deployment to underserved and high-risk populations.
      • Policy Engagement: Advocating for vaccine platform diversification and calling on governments and international donors to break the global reliance on a single supplier for Mpox vaccines.

      David Dodd, Chairman & CEO of GeoVax, commented: “With Mpox cases rapidly rising across Africa and the WHO reaffirming global emergency status, the world must act urgently. The emergence of Clade I across multiple continents and the persistent lack of vaccine access underscore the need for scalable and diversified solutions. GEO-MVA is designed to meet this moment – leveraging our regulatory momentum from the EMA, efforts to accelerate implementation of our continuous manufacturing platform and an unwavering commitment to equitable access. We stand ready to be part of the solution, both scientifically and humanely.”

      About GeoVax

      GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

      Forward-Looking Statements

      This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

      Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

      Company Contact:

      info@geovax.com

      678-384-7220

      Investor Relations Contact:

      geovax@precisionaq.com

      212-698-8696

      Media Contact:

      Jessica Starman

      media@geovax.com 

      GeoVax Labs (GOVX) – 2Q25 Reported With MVA and Gedeptin Trial Updates

      Posted on by slightbourne@noblecapitalmarkets.com


      Tuesday, July 29, 2025

      GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

      Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

      Refer to the full report for the price target, fundamental analysis, and rating.

      GeoVax Reports 2Q25 Financials With Updates Trials For MVA and Gedeptin. GeoVax reported a 2Q25 loss of $5.4 million or $(0.35) per share. Revenues of $0.9 million were for work performed under the BARDA contract prior to its cancellation in April 2025. During the quarter, the EMEA communicated that the GEO-MVA vaccine in development for smallpox/Mpox could skip Phase 1 and 2, then receive approval based on Phase 3 immune markers. The company also amended its trial plans for Gedeptin in HNSCC.

      GEO-MVA Phase 3 Is Expected To Begin In 2H26. As discussed in our Research Note on June 17,GeoVax received Scientific Advice (SA) from the EMA for GEO-MVA smallpox/Mpox vaccine stating the Phase 1 and 2 studies would not been needed. An MAA will only require a single Phase 3 immuno-bridging trial comparing the immune response in healthy volunteers receiving GEO-MVA against the approved vaccine. The study is expected to begin in 2H26.


      Get the Full Report

      Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

      This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

      *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

      Aurania Resources (AUIAF) – Not the Best Way to Stimulate Mining Investment in Ecuador

      Posted on by slightbourne@noblecapitalmarkets.com


      Tuesday, July 29, 2025

      Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

      Refer to the full report for the price target, fundamental analysis, and rating.

      New mining service fee. Ecuador implemented a new mining service fee, Tasa de Fiscalizacion Minera (TASA), on the resource sector. Aurania received notice of the fee associated with its project in Ecuador. The Ecuadorian Control and Regulation Agency (ARCOM) has requested payment of US$2,012,618 by July 31, 2025, representing one month of the total annual fee of US$24,151,420, to help fund ARCOM’s efforts. Because we do not anticipate significant negative repercussions associated with deferring payment, we think Aurania will withhold payment until it becomes clear whether TASA will stand in its current form.

      TASA is being challenged. The new fee represents a significant cost burden for junior exploration companies. Multiple constitutional challenges have been filed in Ecuador and are being analyzed by the Court to determine if the claims will be accepted, which could take several months. If accepted, the constitutional challenges could take several years, and ARCOM may or may not be directed to suspend the collection of fees until claims are resolved. Reasonable accommodations will likely need to be made.


      Get the Full Report

      Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

      This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

      *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

      Release – FAT Brands to Announce Second Quarter 2025 Financial Results On July 30, 2025

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on FAT

      07/28/2025

      LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”), a leading global franchising company and parent company of iconic brands including Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, Fazoli’s and 13 other restaurant concepts, today announced that the Company will host a conference call to review its second quarter 2025 financial results on Wednesday, July 30, 2025 at 4:30 PM ET. A press release with second quarter 2025 financial results will be issued prior to the conference call that day.

      The conference call can be accessed live over the phone by dialing 1-877-704-4453 from the U.S. or 1-201-389-0920 internationally. A replay will be available after the call until Wednesday, August 20, 2025, and can be accessed by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 internationally. The passcode is 13754156. Hosting the call will be Andy Wiederhorn, Chairman, and Ken Kuick, Co-Chief Executive Officer and Chief Financial Officer.

      The conference call will also be webcast live from the corporate website at www.fatbrands.com, under the “Investors” section. A replay of the webcast will be available through the corporate website shortly after the call has concluded.

      About FAT (Fresh. Authentic. Tasty.) Brands

      FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 18 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Smokey Bones, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

      Investor Relations:
      ICR
      Michelle Michalski
      IR-FATBrands@icrinc.com

      Media Relations:

      Erin Mandzik
      emandzik@fatbrands.com

      Release – DLH to Announce Fiscal 2025 Third Quarter Financial Results

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on DLH

      July 28, 2025

      PDF Version

      ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies, will release financial results for the fiscal third quarter ended June 30, 2025 on August 6, 2025 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, August 7, 2025, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow.  

      Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 1191990.

      About DLH
      DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.

      INVESTOR RELATIONS
      Contact: Chris Witty
      Phone: 646-438-9385
      Email: cwitty@darrowir.com

      Release – GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on GOVX

      Study Aims to Validate Thermostable, Self-Administered MVA-Vaccine Platform for Pandemic Preparedness and Global Immunization

      Atlanta, GA – July 28, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today announced the initiation of a research program to evaluate the immunogenicity and stability of GEO-MVA delivered via Vaxxas’ proprietary high-density microarray patch (HD-MAP) platform in preclinical models.

      The proof-of-concept study, conducted at the University of Queensland (UQ) under a research agreement between GeoVax and UniQuest Pty Limited (UQ’s commercialization company), will assess the immune responses, delivery efficiency, and thermostability of GEO-MVA formulated and dried onto HD-MAPs for administration in mice. HD-MAPs offer a needle-free, skin-targeted delivery approach with the potential to enhance immunogenicity and enable distribution without refrigeration.

      “This program represents a potential major step forward in our strategy to expand the versatility of GeoVax’s MVA platform and meet global needs for more accessible, ruggedized, and effective vaccines,” said David Dodd, Chairman and CEO of GeoVax. “Demonstrating that GEO-MVA can be delivered via HD-MAP could lead to more potent immune responses at lower doses, greater thermostability, and eliminate the need for needles – a very compelling profile for both routine immunization and rapid deployment during outbreaks.”

      If successful, the study results will support the development of a thermostable, needle-free GEO-MVA vaccine for pandemic response, biodefense stockpiling, and immunization programs in low- and middle-income countries.

      The HD-MAP platform offers several potential advantages over traditional needle-and-syringe delivery, including:

      • Self-administration in the home, pharmacy, or vaccination hubs;
      • Increased patient acceptance, especially among needle-phobic individuals;
      • Higher immunogenicity, enabling dose-sparing;
      • Thermostability, reducing cold chain reliance;
      • Elimination of sharps waste and needle-stick injuries;
      • Faster deployment in emergency settings with minimal training requirements.

      The Vaxxas HD-MAP platform has demonstrated enhanced immunogenicity in multiple animal model and clinical studies and is being advanced in partnerships with leading pharmaceutical, government entities and foundations. GeoVax recently received favorable scientific advice from the European Medicines Agency (EMA) regarding the development of GEO-MVA. The EMA guidance supports a streamlined regulatory pathway, enabling GeoVax to pursue potential expedited development and approval pathways for GEO-MVA as an additional Mpox vaccine candidate in the EU.

      The current study is supported by GeoVax and conducted by researchers led by A/Prof David Muller and Dr. Chris McMillan at the University of Queensland.

      About GeoVax

      GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

      Forward-Looking Statements

      This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

      Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

      Company Contact:

      info@geovax.com

      678-384-7220

      Investor Relations Contact:

      geovax@precisionaq.com

      212-698-8696

      Media Contact:

      Jessica Starman

      media@geovax.com 

      Release – MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on MAIA

      July 28, 2025 8:01am EDTDownload as PDF

      Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market

      Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months

      CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.

      Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs).

      “FDA’s Fast Track Designation recognizes ateganosine’s potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development,” stated MAIA Chairman and CEO Vlad Vitoc, M.D. “If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. If approved, ateganosine would have a first-to-market competitive position within a $34 billion NSCLC treatment market with significant unmet medical need.”

      NSCLC represents one of the largest global oncology indications. The market was valued at $34.1B in 2024 and is projected to reach $68.8B by 2033 with a projected CAGR of 8.1%.1

      “This is an important milestone for MAIA’s clinical development program. Ateganosine has demonstrated robust preclinical efficacy and superior clinical median overall survival compared to other FDA-approved treatments for NSCLC patients with prior disease progression on platinum-based chemotherapy and anti-PD-(L)1 antibody. Additionally, advanced NSCLC is a devastating disease that clearly meets the criteria for a serious condition with unmet medical need. Both are key criteria for the Fast Track designation,” said K. Robinson Lewis, Vice President, Head of Regulatory and Quality at MAIA. “We intend to utilize the incentives of the Fast Track Program to expedite the development and review of ateganosine and bring patient access sooner.”

      The FDA Fast Track is a process designed to facilitate development and expedite the review of drugs for treating serious conditions and filling an unmet medical need, as in providing a therapy where none exists or which may be potentially better than available therapy. If relevant criteria are met during the Fast Track process, a drug will be eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months).

      MAIA’s most recent data from the pivotal Phase 2 THIO-101 clinical trial of ateganosine as of May 15, 2025 showed median overall survival (OS) of 17.8 months in a heavily pre-treated population. As of the data cut-off date, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months.

      About Ateganosine

      Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

      About THIO-101 Phase 2 Clinical Trial

      THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

      About MAIA Biotechnology, Inc.

      MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

      Forward Looking Statements

      MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

      _____________________________
      1 Custom Market Insights, Global NSCLC Drug Market Size Likely to Surpass at a CAGR of 8.1% By 2033, Apr. 2024

      Investor Relations Contact
      +1 (872) 270-3518
      ir@maiabiotech.com

      Source: MAIA Biotechnology, Inc.

      Released July 28, 2025

      Release Aurania Provides Update on New Mining Service Fee in Ecuador

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on AUIAF

      July 28, 2025 7:17 AM EDT | Source: Aurania Resources Ltd.

      Toronto, Ontario–(Newsfile Corp. – July 28, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) provides an update on the Ecuadorian government’s recently imposed new Mining Service Fee (Tasa de Fiscalización Minera or TASA) on the resource sector.

      As previously disclosed in a press release dated June 11, 2025, the resolution put forth by the Ecuadorian Control and Regulation Agency (“ARCOM”) in relation to new administrative fees for the mining sector has now taken effect and the Company has received notice of the fee as it applies to its project in Ecuador. The resolution was published in the Official Registry on June 20, 2025, and on June 27, 2025, ARCOM issued a resolution outlining the official regulations detailing the payment collection mechanism for the administrative fee. Under this new regulation, ARCOM has requested that the Company pay US$2,012,618 by July 31, 2025, equivalent to one month of the total annual administrative fee of $24,151,420. These annual fees amount to more than Aurania’s current market capitalisation and present an unsustainable cost burden for Aurania and other companies operating within the sector. These new fees are especially burdensome for companies working in early-stage exploration, which is a critical component of the mining pipeline, as standalone exploration-stage companies typically do not generate revenue and therefore rely solely on investment through capital markets to fund their projects.

      Aurania’s Chairman, President & CEO, Dr. Keith Barron commented, “Aurania has a long history of working and investing in Ecuador. I’m a big believer in our project there, and I value the cooperative relationships that we have built to date. However, the new fees are excessive and disproportionate. The Mining Chamber along with other companies working in Ecuador are appalled by the administrative fee. As we continue to work on possible solutions we will always endeavour to be fully transparent with our shareholders and will continue to provide updates on this evolving situation.”

      To our knowledge, four constitutional challenges against the new administrative fees have been presented in Ecuador and are being analyzed by the Court to determine if the claims will be accepted. The decision whether or not to accept the claims may take several months and, if accepted, the constitutional challenges could take several years. In the meantime, if the claims are accepted, ARCOM may or may not be directed to halt the collection of the fees.

      The Company will wait for these procedures to follow their course, and it will assess its legal rights and options for further courses of action.

      2025 Concession Fees

      In March 2025, the Company filed a request to enter into an agreement for the deferred payment of the annual concession fees with the Ecuadorian tax authority (SRI) which total US$2,441,227 – see press release dated March 31, 2025. As part of this process, the Company will make a first payment of US$488,245 equivalent to 20% of the 2025 concession fees plus accumulated interest by August 8, 2025. The Company expects to continue to negotiate the payment terms for the balance of its 2025 concession fees. A failure to reach an agreement could result in the remaining balance becoming immediately due and payable and a potential forfeiture of the mineral concessions.

      About Aurania

      Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

      Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, X (formerly Twitter) at https://x.com/AuraniaLtd , and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

      For further information, please contact:

      Carolyn Muir
      VP Corporate Development & Investor Relations
      Aurania Resources Ltd.
      (416) 367-3200
      carolyn.muir@aurania.com

      Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

      Forward-Looking Statements

      This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management’s current expectations and assumptions. The forward-looking information includes Aurania’s objectives, goals and future plans in respect of the administration fee imposed by ARCOM and the status and negotiation for the deferred payment of the annual concession fees with the Ecuadorian tax authority.Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to Aurania, including the assumption that, there will be no material adverse change in metal prices, all necessary consents, licenses, permits and approvals will be obtained, including various local government licenses and the market. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things: an inability to fund the administrative fees imposed by ARCOM on the mining sector which could render the Company insolvent; an inability to fund or extend the payment of Ecuador mineral concession fees which are due and payable and which could result in the forfeiture of such mineral concessions; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; the inability to recover and process mineralization using known mining methods; the presence of deleterious mineralization or the inability to process mineralization in an environmentally acceptable manner; commodity prices, supply chain disruptions, restrictions on labour and workplace attendance and local and international travel; a failure to obtain or delays in obtaining the required regulatory licenses, permits, approvals and consents; an inability to access financing as needed; a general economic downturn, a volatile stock price, labour strikes, political unrest, changes in the mining regulatory regime governing Aurania; a failure to comply with environmental regulations; a weakening of market and industry reliance on precious metals and base metals; and those risks set out in the Company’s public documents filed on SEDAR+. Aurania cautions the reader that the above list of risk factors is not exhaustive. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

      info

      SOURCE: Aurania Resources Ltd.

      Release – The GEO Group Closes Sale of Company-Owned Lawton Correctional Facility in Oklahoma for $312 Million

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on GEO

      July 28, 2025

      View PDF

      BOCA RATON, Fla.–(BUSINESS WIRE)–Jul. 28, 2025– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that on July 25, 2025, the Company completed the sale of the GEO-owned Lawton Correctional Facility (the “Lawton Facility”) located in Lawton, Oklahoma to the State of Oklahoma for $312 million and simultaneously transitioned the Lawton Facility operations to the Oklahoma Department of Corrections.

      As previously disclosed, GEO expects to use the net proceeds from the sale of the Lawton Facility to acquire the 770-bed Western Region Detention Facility located in San Diego, California in a like kind real estate property exchange expected to close on July 31, 2025, and to pay off additional senior secured debt, including the remaining balance of the Term Loan B outstanding under the Company’s recently amended Credit Agreement. These transactions are expected to reduce GEO’s total net debt to approximately $1.47 billion and position GEO to consider potential future capital returns.

      George C. Zoley, Executive Chairman of GEO, said, “We believe that the successful sale of our Lawton Facility is representative of the intrinsic value of our Company-owned facilities, which now total approximately 50,000 beds. We believe this important transaction is a significant deleveraging event that further strengthens our balance sheet and represents an important step to position our Company to consider potential future capital returns. Our management team and Board of Directors remain focused on the disciplined allocation of capital to enhance long-term value for our shareholders.”

      About The GEO Group

      The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 74,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 19,000 employees.

      Use of forward-looking statements

      This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

      Pablo E. Paez 
      Executive Vice President, Corporate Relations 
      (866) 301 4436

      Source: The GEO Group, Inc.